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Abstract In lymphocytes, glucocorticoids (GC)- and interleu-
kin-4-signaling pathways are known to interact, as evidenced by
inhibition of IL-4-mediated proliferation by dexamethasone or
suppression of GC-induced apoptosis by IL-4. In this study, we
characterized the molecular basis for this reciprocal interference.
We report that, in murine CTLL-2 cells, IL-4 inhibits GC-
induced MMTV (mouse mammary tumor virus) promoter
transactivation, and that GC suppress IL-4-induced transactiva-
tion of a STAT6 (signal transducers and activators of tran-
scription 6)-responsive promoter without affecting IL-4-
stimulated STAT6 DNA-binding. Moreover, we evidenced a
physical association between GC receptor and STAT6, which
proved to be functionally relevant, since STAT6 overexpression
increased the IL-4 inhibitory effect on GC-induced MMTV
transactivation. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Interleukin-4 (IL-4) is a critical regulatory cytokine of the
immune response. In naive CD4 T-helper (Th) lymphocytes,
IL-4 promotes Th2 cell di¡erentiation, driving allergic and
humoral-mediated immunity [1]. The transcriptional response
to IL-4 is partly mediated through STAT6 (signal transducers
and activators of transcription 6) and mice de¢cient in STAT6
show impairment of numerous IL-4-mediated functions [2,3].
Glucocorticoids (GC) display profound immunomodulatory
properties and are therefore widely used in the therapy of
in£ammatory and allergic diseases. These molecules exert
their biological e¡ects through binding to the GC receptor
(GR), which is a ligand-activated transcription factor regulat-
ing either positively or negatively the expression of target
genes [4]. Apart from the association with GC-responsive el-
ements (GREs) in the promoter regions of these genes, GR
can establish protein^protein interactions with other tran-
scription factors such as AP-1 [5^7], NF-UB [8], or members
of the STAT family. The latter interactions result in either
synergistic enhancement or inhibition of the transcriptional
activities of these factors. Indeed, in COS-7 cells stimulated
with prolactin, STAT5 synergizes with GC on the L-casein
promoter, but antagonizes GC-induced mouse mammary tu-
mor virus (MMTV)-long terminal repeat (LTR) promoter ac-
tivity [9^12]. In the rat hepatoma cell line H4IIE and in COS-
7 cells stimulated with IL-6, STAT3 was shown to synergize
with GC on the rat Q-¢brinogen promoter or on the MMTV-
LTR promoter [13]. A transcriptional cooperation between
STAT1, the GR and the Ets family transcription factor
PU.1 was described in monocytes, resulting in the enhance-
ment by the synthetic GC dexamethasone (DEX) of the inter-
feron (IFN) Q-induced expression of FcQRI [14]. Furthermore,
GC were recently shown to block IL-12-induced STAT4 phos-
phorylation without a¡ecting IL-4-induced STAT6 phosphor-
ylation [15]. Taken together, these results show that, despite
the high degree of homology existing between the di¡erent
STAT proteins, their functional interactions with GR do
not necessarily display a common mechanism.
DEX was previously shown to block the IL-4-driven pro-
liferation of CTLL-2 cells [16]. In addition, IL-4 speci¢cally
inhibits DEX-induced apoptosis in Th2 cells [17]. The aim of
this work was to characterize the molecular basis for the func-
tional interaction between IL-4 and the GR transduction
pathways. We characterized a transcriptional interference be-
tween these two pathways, and could provide evidence for a
physical association between the GR and STAT6.
2. Materials and methods
2.1. Chemicals and reagents
Recombinant human IL-2 was a gift from Chiron B.V., Amster-
dam, The Netherlands. Recombinant murine IL-4 was a gift of Ster-
ling-Winthrop (Rensealer, USA). DEX was purchased from Sigma
(L’Isle D’Abeau, France) and Luciferase Assay System from Promega
(Madison, WI, USA).
2.2. Cell culture
The murine IL-2-dependent cytotoxic T-cell line CTLL-2 was cul-
tured in complete medium: RPMI 1640 medium (Gibco) containing
2 mM L-glutamine, 0.1 mg/ml streptomycin, 100 U/ml penicillin (Gib-
co), 50 WM 2-mercaptoethanol (Sigma), 1% sodium pyruvate (Gibco),
10% fetal calf serum and 1 ng/ml IL-2.
2.3. Plasmids
pLTR-Luc plasmid contains the entire MMTV-LTR coupled to the
luciferase reporter gene [18]. p200-Luc plasmid displays a 5P-end dele-
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tion up to the 3200 position relative to the transcriptional initiation
site (+1). p2GRE104-Luc plasmid was constructed by inserting two
synthetic consensus GREs immediately upstream of the proximal re-
gion of the promoter (3104/+1). The GRE5-EBV-TATA-CAT plas-
mid was a kind gift of S. Mader [19]. The STAT6-Luc and pcDNA3:1-
myc-STAT6 plasmids were a kind gift of A. Duschl (University of
Wu«rzburg, Germany).
2.4. Transfections
CTLL-2 cells (107) were electroporated using a Bio-Rad gene pulser
(Ivry-Sur-Seine, France) set at 250 V and 960 WF. Selection of stably
transfected clones (CTLL-2 pLTR, CTLL-2 p200 or CTLL-2
p2GRE104) was performed using 800 Wg/ml G418 (Gibco) and limit-
ing dilution. Several clones were tested to assess the variability due to
the site of integration in the cellular genome and experiments were
performed with representative clones of CTLL-2 pLTR, CTLL-2 p200
and CTLL-2 p2GRE104 cells.
2.5. Reporter gene assays
2.5.1. Luciferase assay. Luciferase levels were measured according
to the manufacturer’s protocol (Promega). Protein extracts in equiv-
alent protein concentration samples were mixed with 100 Wl of Lucif-
erase Assay Reagent. Luciferase activity was determined at 25‡C after
1 min with a luminometer (LKB Wallac, Turku, Finland). CAT
(chloramphenicol acetyl transferase) assay: CAT assay was performed
as previously described [20] and conversion of chloramphenicol was
quanti¢ed using a Storm 840 Phosphorimager and the Imagequant
software (molecular Dynamics, Sunnyvale, USA).
2.6. DNA a⁄nity precipitation of STAT proteins
DNA a⁄nity precipitation method was performed as previously
described [21] using a 5P-biotinylated double-stranded GAS (IFNQ-
activated sequence) linked to streptavidin-agarose beads (Sigma).
Western blot analysis was subsequently performed with a speci¢c
anti-STAT6 antibody (M200, Santa Cruz Biotechnology, USA), or
with an anti-STAT5 rabbit polyclonal antiserum raised in the labora-
tory.
2.7. Co-immunoprecipitation assays
CTLL-2 cells were deprived of IL-2 for 12 h, and then stimulated
for 1 h with IL-4 (5 ng/ml) and/or DEX (100 nM), or left untreated.
Nuclear or cytoplasmic extracts were ¢rst incubated for 30 min at 4‡C
with Protein A Sepharose beads (Sigma) and pre-immune serum. The
pre-cleared lysate was then incubated overnight at 4‡C with either an
anti-GR antibody (M20, Santa Cruz) or an anti-STAT6 antibody
(M200, Santa Cruz) pre-coupled to Protein A Sepharose beads. Im-
mune complexes were washed three times with lysis bu¡er, and ana-
lyzed by SDS^PAGE using anti-STAT6 or anti-GR antibodies, re-
spectively.
3. Results and discussion
3.1. E¡ect of IL-4 on DEX-induced GR transcriptional activity
CTLL-2 is a murine IL-2-dependent T-lymphocyte cell line
that also responds to IL-4. Indeed, IL-4 promotes survival
and proliferation of these cells in absence of IL-2 and protects
them from DEX-induced apoptosis (data not shown). The
e¡ect of IL-4 on GR transcriptional activity was evaluated
in CTLL-2 cells stably transfected with the pLTR-Luc plas-
mid containing the MMTV promoter coupled to the luciferase
reporter gene (CTLL-2 pLTR cells). A 12 h treatment of
CTLL-2 pLTR cells with 100 nM DEX results in a 10-fold
induction of luciferase activity (Fig. 1A). IL-4 alone does not
a¡ect the promoter activity (data not shown). Concomitant
addition of increasing amounts of IL-4 (1, 5 or 10 ng/ml) with
DEX produces a concentration-dependent inhibition of GR
transcriptional activity (0, 51 and 67% inhibition, respec-
tively). In its proximal region, upstream of the TATA box,
the MMTV promoter is composed of a cluster of four GREs,
as well as of binding sites for ubiquitous transcription factors
such as NF-1 and Oct-1. The 5P-end of the promoter was
described to contain numerous cell type-speci¢c positive or
negative regulatory regions. Given the composite nature of
this promoter, we explored, by the mean of 5P-end deletions
of the promoter, the existence of one (or more) regulatory
element(s) responsible for the inhibitory e¡ect of IL-4. The
Fig. 1. E¡ect of IL-4 on DEX-induced GR transcriptional activity
in CTLL-2 cells. A: IL-4 inhibits DEX-induced MMTV-LTR activ-
ity in stably transfected CTLL-2 pLTR cells. CTLL-2 pLTR cells
were treated for 12 h with DEX (100 nM) and/or IL-4 (1, 5 or 10
ng/ml), or left untreated. Fold induction was calculated as the ratio
of arbitrary luciferase units in cells treated with DEX compared to
untreated cells, or in cells treated with DEX and IL-4 compared to
cells treated with IL-4 alone. The value 1 was consequently a¡ected
to the basal level measured in non-treated cells. A representative ex-
periment out of four is shown here. B: The most proximal region
of the MMTV-LTR promoter (3104/+1) is necessary and su⁄cient
to mediate the inhibitory e¡ect of IL-4. CTLL-2 p200 and CTLL-2
p2GRE104 cells were treated for 12 h with DEX (100 nM) and/or
IL-4 (5 ng/ml), or left untreated. Results of a representative experi-
ment out of three. C: IL-4 does not inhibit DEX-induced GRE5-
EBV-TATA-CAT activity in CTLL-2 cells. CTLL-2 cells were tran-
siently transfected with the GRE5-EBV-TATA-CAT plasmid, and
treated for 12 h with DEX (100 nM) and/or IL-4 (5 ng/ml), or left
untreated. Percentage of chloramphenicol conversion represents the
ratio between acetylated chloramphenicol and total chloramphenicol
(acetylated and non-acetylated). A representative experiment out of
two is shown here.
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p200-Luc construct, which displays the proximal part of the
promoter (including the four GREs), was stably transfected in
CTLL-2 cells (CTLL-2 p200 cells). IL-4, at 5 ng/ml, reduced
by 60% the DEX-induced transactivation of the promoter
(Fig. 1B), indicating that sequences located upstream of the
3200 position can be deleted without impairing the IL-4 in-
hibitory e¡ect. To further investigate the role played by ele-
ments located in the region spanning from 3200 to 3104, we
constructed the p2GRE104-Luc plasmid and stably trans-
fected this plasmid in CTLL-2 cells. Again, IL-4 displayed
an inhibitory e¡ect on DEX-induced luciferase activity (Fig.
1B), suggesting that the IL-4 inhibitory e¡ect on GC-induced
MMTV transactivation requires the most proximal part of the
promoter to occur. A possible explanation could be that IL-4
might prevent binding of GR to GREs. However, the inhib-
itory e¡ect of IL-4 on GR transcriptional activity was not
found with a simple synthetic promoter, composed of ¢ve
palindromic GREs adjacent to a minimal TATA box
(GRE5-EBV-TATA-CAT) (Fig. 1C). These results suggest
that the inhibitory e¡ect of IL-4 on GC-stimulated MMTV
promoter activity is dependent on the promoter context, and
does not rely on an IL-4-driven impairment of GR^DNA or
ligand-binding activity.
3.2. E¡ect of STAT6 on GC-induced MMTV-luc
transactivation
We then attempted to identify the IL-4 signal transduction
pathway responsible for the inhibition of GC-induced MMTV
transactivation. Several STAT family transcription factors
were previously described as modulators of the GR transcrip-
tional activity, particularly STAT5 [9^12]. We ¢rst veri¢ed
that, in CTLL-2 cells, IL-4 induces STAT6 but not STAT5,
since in the murine pro-B-cell line Ba/F3 and in pre-activated
human T-cells, IL-4 was shown to activate the STAT5 tran-
scription factor in addition to STAT6 [22]. We then used a 5P-
biotinylated GAS oligonucleotide linked to streptavidin-aga-
rose beads to measure IL-4-stimulated DNA-binding activity
of STAT5 and STAT6 in CTLL-2 cells. GAS-bound proteins
were probed with both anti-STAT5 and anti-STAT6 antibod-
ies. After 1 h of IL-4 treatment (Fig. 2), a strong activation of
STAT6^, but not of STAT5^DNA-binding is measured, rul-
ing out any participation of STAT5 in the inhibitory e¡ect of
IL-4 on GR transcriptional activity. Furthermore, IL-2 stim-
ulates STAT5 DNA-binding activity, but the combination of
the two cytokines does not a¡ect the levels of STAT5 or
STAT6 activation (Fig. 2).
To investigate the involvement of STAT6 in the inhibitory
e¡ect of IL-4 on GR transcriptional activity, we transiently
transfected CTLL-2 p2GRE104-Luc cells with an expression
vector for the wild type form of STAT6 fused to a myc tag
(pcDNA3:1-myc-STAT6) or with a control vector (pcDNA3:1).
Expression of the Myc-STAT6 protein was obtained after
transfection by a 24 h culture in presence of 500 pg/ml IL-2
(see Fig. 3, right insert). At the concentration of 1 ng/ml, IL-4
inhibition of GC-induced p2GRE104-Luc transactivation is
enhanced by a 2-fold factor in cells overexpressing STAT6
(46% inhibition) compared to cells transfected with the con-
trol vector (25% inhibition) (Fig. 3). The di¡erence is less
marked at 5 ng/ml IL-4 (48 versus 37%), suggesting that the
maximum achievable inhibition was reached in STAT6 over-
expressing cells. These results strongly support the hypothesis
that STAT6 is an important modulator of GR-mediated
MMTV transactivation.
3.3. E¡ect of GC on IL-4-induced STAT6 transcriptional
activity
To further document the functional interaction between GR
and STAT6, we transfected CTLL-2 cells with a STAT6-Luc
reporter construct, containing ¢ve STAT6-responsive elements
from the human IgE class switching promoter coupled to a
minimal TATA box. Compared to cells treated with IL-4
alone, incubation of the cells with a saturating dose of DEX
(100 nM) and 0.1 or 0.2 ng/ml IL-4 results in 44 and 46%
inhibition of the transcriptional activation of the promoter,
respectively (Fig. 4A). But increasing the concentration of IL-
4 (1 and 5 ng/ml) causes a fall in the percentage of inhibition
(30 and 7%, respectively). These results suggest a mechanism
of inhibition where DEX-activated GR might be a rate limit-
ing component compared to IL-4-stimulated STAT6. In COS-
7 cells transiently transfected with STAT6 and GR, Moriggl
and collaborators measured an enhancement by DEX of IL-4-
induced activation of L-casein gene transcription [23]. The
e¡ect of GC on STAT6 transcriptional activity may thus de-
pend on the promoter context, and also probably on the cell
type.
Fig. 2. Induction by IL-4 of STAT6^ but not STAT5^DNA-binding
activity. CTLL-2 cells were deprived of IL-2 for 3 h, and then
treated for 1 h with IL-2 (1 ng/ml), IL-4 (5 ng/ml), IL-2 and IL-4,
or left untreated. DNA-binding of STAT5 and STAT6 was then
measured by the DNA a⁄nity precipitation method and bound pro-
teins were probed with either an anti-STAT5 or an anti-STAT6
antibody.
Fig. 3. E¡ect of STAT6 overexpression on MMTV-luc transactiva-
tion. CTLL-2 p2GRE104-Luc cells (clone 19) were transiently trans-
fected with pcDNA3:1-myc-STAT6 or with a control vector
(pcDNA3:1). Cells were treated for 12 h with DEX (100 nM) and/or
IL-4 (1 or 5 ng/ml), or left untreated. Fold induction was calculated
as the ratio of arbitrary luciferase units in cells treated with DEX
compared to untreated cells, or in cells treated with DEX and IL-4
compared to cells treated with IL-4 alone. Results are expressed in
percentage of inhibition. Representative results out of two experi-
ments.
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We then assessed if DEX treatment could impair IL-4-
stimulated DNA-binding activity of STAT6. Results pre-
sented in Fig. 4B show that STAT6 DNA-binding activity is
not modi¢ed when cells are concomitantly incubated with
DEX and IL-4 for 15 or 30 min. Recently, it was reported
that a 6 or 18 h pretreatment of T-lymphocytes with DEX
does not alter the IL-4-induced STAT6 phosphorylation [15].
Despite the di¡erent experimental procedure, these latter re-
sults are in accordance with our ¢ndings. We can thus rule out
the inhibition of STAT6 DNA-binding activity as a mecha-
nism of inhibition of STAT6 transcriptional activity by GC.
3.4. Physical interaction between STAT6 and the GR
We postulated that STAT6 might physically interact with
the GR, explaining the transcriptional interference existing
between the two factors. Co-immunoprecipitation experiments
were performed with an anti-GR antibody using cytoplasmic
and nuclear extracts from CTLL-2 cells deprived of IL-2 for
12 h and treated for 1 h with DEX (100 nM) or DEX and IL-
4 (5 ng/ml). Blotting of the GR immuno-complex with an
anti-STAT6 antibody allowed us to detect co-precipitated
STAT6 (Fig. 5A). Indeed, an association between GR and
STAT6 was evidenced, in the cytoplasmic as well as in the
nuclear compartment. Apparently, the GR^STAT6 complex is
more abundant in the cytoplasmic compartment. Moreover,
the interaction is weak in DEX-treated cells, but is strongly
enhanced by a concomitant treatment with IL-4. The physical
interaction between GR and STAT6 was con¢rmed by immu-
noprecipitation experiments on cytoplasmic extracts with an
anti-STAT6 antibody, and subsequent immunoblotting with
an anti-GR antibody (Fig. 5B). Our results suggest that the
anti-STAT6 antibody we are using more e⁄ciently recognizes
the activated form of the protein. Consequently, only a qual-
itative interpretation of these results can be made, concluding
in a physical association of GR and STAT6 in the presence of
DEX or DEX and IL-4. It remains to be clari¢ed whether
GR^STAT6 interaction is direct or not, and which role is
played by the IL-4 activation of STAT6 in this interaction.
It is interesting to note that this physical interaction does not
impede the DNA-binding activity of STAT6 (see Fig. 3B). A
physical association between the GR and STAT5 [9], or
STAT3 [13], but not STAT1 [14], was previously described.
We report here for the ¢rst time that GR and STAT6 physi-
cally interact with each other in T-lymphocytes.
3.5. Concluding remarks
In this work, we provide evidence for a functional and
physical interaction between GR and STAT6. Further studies
are needed to elucidate the mechanism of GR and STAT6
mutual transcriptional repressive activities. A protein^protein
interaction could cause sterical hindrance and prevent GR
and STAT6 to establish appropriate contacts with the basal
transcriptional machinery as recently suggested for NF-UB
[24]. GR and STAT6, which have both been described to
interact with the coactivator CBP (CREB-binding protein)/
p300 [25,26], could compete for limiting amounts of CBP
within the cell, as previously described for the AP-1 inhibition
by nuclear receptors [26]. GR and STAT6 could also form a
ternary complex with CBP, as recently described for the mu-
tual antagonism between GR and NF-UB [27]. We are cur-
rently investigating these hypotheses.
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Fig. 4. E¡ect of GC on IL-4-induced STAT6 transcriptional activity
and DNA-binding. A: CTLL-2 cells were transiently transfected
with the STAT6-Luc plasmid and treated for 12 h with DEX (100
nM) and/or IL-4 (0.1, 0.2, 1 or 5 ng/ml), or left untreated. Fold in-
duction was calculated as the ratio of arbitrary luciferase units in
cells treated with IL-4 compared to untreated cells, or in cells
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alone. Results are expressed in percentage of inhibition. B: CTLL-2
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(100 nM), or left untreated. DNA-binding of STAT6 was then mea-
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were probed with an anti-STAT6 antibody. WCE: whole cell ex-
tract. Representative results out of three experiments.
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